<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="HIV-1 (Clouser et al., 2010)HIV-1 – synergy in combination with" exact="gemcitabine" post="(Clouser et al., 2010)HIV-1 – synergy in combination with"/>
 <result pre="(2010); (Clouser et al., 2012)HIV-1 – synergy in combination with" exact="decitabine" post="(Clouser et al., 2010)MuLV (Clouser et al., 2012)HIV-2 (Beach"/>
 <result pre="et al., 2015; Zhang et al., 2017)Enteroviruses – synergy with" exact="ribavirin" post="(Kang et al., 2015)Rhinoviruses (Song et al., 2017)HCV (Beran"/>
 <result pre="anti-inflammatory properties (Van Linthout et al., 2018) Tenofovir disoproxil Acyclic" exact="adenosine" post="nucleotide analogue HIV (2001)HBV (2008) Tenofovir alafenamide Acyclic adenosine"/>
 <result pre="Acyclic adenosine nucleotide analogue HIV (2001)HBV (2008) Tenofovir alafenamide Acyclic" exact="adenosine" post="nucleotide analogue HBV (2016)HIV (several combination, see Table 2)"/>
 <result pre="analogue HSV (1980) Metastatic colorectal cancer (2015) in combination with" exact="tipiracil" post="Mycoplasma pneumonia (Sun and Wang, 2013) Valaciclovir Acyclic guanosine"/>
 <result pre="Approved nucleos(t)ide inhibitors of HBV polymerase include lamivudine, adefovir, telbivudine," exact="entecavir" post="and tenofovir. Two of them, lamivudine and tenofovir, exhibit"/>
 <result pre="include lamivudine, adefovir, telbivudine, entecavir and tenofovir. Two of them," exact="lamivudine" post="and tenofovir, exhibit multi-target activity and are also approved"/>
 <result pre="of the pentose ring. Tenofovir is an acyclic analogue of" exact="adenosine" post="5′-monophosphate and is marketed in the form of two"/>
 <result pre="5′-monophosphate and is marketed in the form of two prodrugs:" exact="tenofovir" post="disoproxil (TDF, Viread) and tenofovir alafenamide (TAF, Vemlidy). The"/>
 <result pre="the form of two prodrugs: tenofovir disoproxil (TDF, Viread) and" exact="tenofovir" post="alafenamide (TAF, Vemlidy). The roles of the two prodrugs"/>
 <result pre="by De Clercq (De Clercq, 2018). The tendency to substitute" exact="tenofovir" post="disoproxil with tenofovir alafenamide in both anti-HIV and anti-HBV"/>
 <result pre="(De Clercq, 2018). The tendency to substitute tenofovir disoproxil with" exact="tenofovir" post="alafenamide in both anti-HIV and anti-HBV treatment has been"/>
 <result pre="have shown that this drug is significantly more effective than" exact="lamivudine" post="and less likely to cause resistance. Moreover, telbivudine has"/>
 <result pre="effective than lamivudine and less likely to cause resistance. Moreover," exact="telbivudine" post="has some pleiotropic immunomodulatory and anti-inflammatory properties (Rehermann and"/>
 <result pre="properties (Rehermann and Bertoletti, 2015). Recently, it was shown that" exact="telbivudine" post="confers endothelial-protective effects on B19V-infected endothelial cells and improves"/>
 <result pre="Clercq, 2018). One of the exceptions is the use of" exact="ribavirin" post="in combination with standard therapy to enhance the current"/>
 <result pre="positively affect HBV treatment. A study on anti-HBV treatment with" exact="ribavirin" post="and tenofovir, compared to tenofovir treatment alone, is currently"/>
 <result pre="study on anti-HBV treatment with ribavirin and tenofovir, compared to" exact="tenofovir" post="treatment alone, is currently in a phase 3 clinical"/>
 <result pre="target multiple stages of the HIV life cycle. Lamivudine and" exact="tenofovir" post="are among the most important drugs used in combination"/>
 <result pre="24 small-molecule combinations most frequently utilized as drug components, anti-HIV" exact="lamivudine" post="occurred 15 times, while tenofovir disoproxil occurred 9 times."/>
 <result pre="utilized as drug components, anti-HIV lamivudine occurred 15 times, while" exact="tenofovir" post="disoproxil occurred 9 times. Lamivudine and tenofovir have been"/>
 <result pre="15 times, while tenofovir disoproxil occurred 9 times. Lamivudine and" exact="tenofovir" post="have been combined with other NRTIs (e.g., abacavir, emtricitabine,"/>
 <result pre="Sciences, 2001 (tenofovir disoproxil fumarate)Truvada, Gilead Sciences, 2004 (emtricitabine +" exact="tenofovir" post="disoproxil fumarate)Atripla, Gilead Sciences, Bristol-Myers Squibb, 2006 (emtricitabine +"/>
 <result pre="tenofovir disoproxil fumarate)Atripla, Gilead Sciences, Bristol-Myers Squibb, 2006 (emtricitabine +" exact="efavirenz" post="+ tenofovir disoproxil fumarate)Complera, Gilead Sciences, 2011 (emtricitabine +"/>
 <result pre="fumarate)Atripla, Gilead Sciences, Bristol-Myers Squibb, 2006 (emtricitabine + efavirenz +" exact="tenofovir" post="disoproxil fumarate)Complera, Gilead Sciences, 2011 (emtricitabine + rilpivirine +"/>
 <result pre="efavirenz + tenofovir disoproxil fumarate)Complera, Gilead Sciences, 2011 (emtricitabine +" exact="rilpivirine" post="+ tenofovir disoproxil fumarate)Stribild, Gilead Sciences, 2012 (elvitegravir +"/>
 <result pre="tenofovir disoproxil fumarate)Complera, Gilead Sciences, 2011 (emtricitabine + rilpivirine +" exact="tenofovir" post="disoproxil fumarate)Stribild, Gilead Sciences, 2012 (elvitegravir + cobicistat +"/>
 <result pre="rilpivirine + tenofovir disoproxil fumarate)Stribild, Gilead Sciences, 2012 (elvitegravir +" exact="cobicistat" post="+ emtricitabine + tenofovir disoproxil fumarate)Delstrigo, Merck, 2018 (doravirine"/>
 <result pre="tenofovir disoproxil fumarate)Stribild, Gilead Sciences, 2012 (elvitegravir + cobicistat +" exact="emtricitabine" post="+ tenofovir disoproxil fumarate)Delstrigo, Merck, 2018 (doravirine + lamivudine"/>
 <result pre="fumarate)Stribild, Gilead Sciences, 2012 (elvitegravir + cobicistat + emtricitabine +" exact="tenofovir" post="disoproxil fumarate)Delstrigo, Merck, 2018 (doravirine + lamivudine +tenofovir disoproxil"/>
 <result pre="+ emtricitabine + tenofovir disoproxil fumarate)Delstrigo, Merck, 2018 (doravirine +" exact="lamivudine" post="+tenofovir disoproxil fumarate)Cimduo, Mylan Pharmaceuticals, 2018 (lamivudine + tenofovir"/>
 <result pre="+ lamivudine +tenofovir disoproxil fumarate)Cimduo, Mylan Pharmaceuticals, 2018 (lamivudine +" exact="tenofovir" post="disoproxil fumarate)Symfi Lo, Mylan Pharmaceuticals, 2018 (efavirenz + lamivudine"/>
 <result pre="+ tenofovir disoproxil fumarate)Symfi Lo, Mylan Pharmaceuticals, 2018 (efavirenz +" exact="lamivudine" post="+ tenofovir disoproxil fumarate) Tenofovir alafenamide fumarate (TAF) Vemlidy,"/>
 <result pre="disoproxil fumarate)Symfi Lo, Mylan Pharmaceuticals, 2018 (efavirenz + lamivudine +" exact="tenofovir" post="disoproxil fumarate) Tenofovir alafenamide fumarate (TAF) Vemlidy, Gilead, 2016"/>
 <result pre="(TAF) Vemlidy, Gilead, 2016 Genvoya, Gilead Sciences 2015 (elvitegravir +" exact="cobicistat" post="+ emtricitabine, + tenofovir alafenamide)Descovy, Gilead Sciences, 2016 (emtricitabine"/>
 <result pre="Genvoya, Gilead Sciences 2015 (elvitegravir + cobicistat + emtricitabine, +" exact="tenofovir" post="alafenamide)Descovy, Gilead Sciences, 2016 (emtricitabine + tenofovir alafenamide)Odefsey, Gilead"/>
 <result pre="+ emtricitabine, + tenofovir alafenamide)Descovy, Gilead Sciences, 2016 (emtricitabine +" exact="tenofovir" post="alafenamide)Odefsey, Gilead Sciences, 2016 (emtricitabine + rilpivirine + tenofovir"/>
 <result pre="2016 (emtricitabine + tenofovir alafenamide)Odefsey, Gilead Sciences, 2016 (emtricitabine +" exact="rilpivirine" post="+ tenofovir alafenamide)Symtuza, Janssen Therapeutics, 2018 (darunavir + cobicistat"/>
 <result pre="+ tenofovir alafenamide)Odefsey, Gilead Sciences, 2016 (emtricitabine + rilpivirine +" exact="tenofovir" post="alafenamide)Symtuza, Janssen Therapeutics, 2018 (darunavir + cobicistat + emtricitabine"/>
 <result pre="+ rilpivirine + tenofovir alafenamide)Symtuza, Janssen Therapeutics, 2018 (darunavir +" exact="cobicistat" post="+ emtricitabine + tenofovir alafenamide)Biktarvy, Gilead Sciences, 2018 (bictegravir"/>
 <result pre="+ tenofovir alafenamide)Symtuza, Janssen Therapeutics, 2018 (darunavir + cobicistat +" exact="emtricitabine" post="+ tenofovir alafenamide)Biktarvy, Gilead Sciences, 2018 (bictegravir + emtricitabine"/>
 <result pre="alafenamide)Symtuza, Janssen Therapeutics, 2018 (darunavir + cobicistat + emtricitabine +" exact="tenofovir" post="alafenamide)Biktarvy, Gilead Sciences, 2018 (bictegravir + emtricitabine + tenofovir"/>
 <result pre="+ emtricitabine + tenofovir alafenamide)Biktarvy, Gilead Sciences, 2018 (bictegravir +" exact="emtricitabine" post="+ tenofovir alafenamide) Lamivudine (3TC) Epivir, Glaxo Wellcome, 1998"/>
 <result pre="+ tenofovir alafenamide)Biktarvy, Gilead Sciences, 2018 (bictegravir + emtricitabine +" exact="tenofovir" post="alafenamide) Lamivudine (3TC) Epivir, Glaxo Wellcome, 1998 Combivir, ViiV"/>
 <result pre="Healthcare, 2000 (lamivudine + zidovudine)Trizivir, ViiV Healthcare, 2000 (abacavir +" exact="lamivudine" post="+ zidovudine)Epzicom, ViiV Healthcare, 2004 (abacavir + lamivudine)Triumeq, ViiV"/>
 <result pre="Healthcare, 2004 (abacavir + lamivudine)Triumeq, ViiV HealthCare, 2014 (abacavir +" exact="dolutegravir" post="+ lamivudine)Dutrebis, Merck, 2015 (lamivudine + raltegravir)Delstrigo, Merck, 2018"/>
 <result pre="lamivudine)Dutrebis, Merck, 2015 (lamivudine + raltegravir)Delstrigo, Merck, 2018 (doravirine +" exact="lamivudine" post="+tenofovir disoproxil fumarate)Cimduo, Mylan Pharmaceuticals, 2018 (lamivudine + tenofovir"/>
 <result pre="+ lamivudine +tenofovir disoproxil fumarate)Cimduo, Mylan Pharmaceuticals, 2018 (lamivudine +" exact="tenofovir" post="disoproxil fumarate)Symfi Lo, Mylan Pharmaceuticals, 2018 (efavirenz + lamivudine"/>
 <result pre="+ tenofovir disoproxil fumarate)Symfi Lo, Mylan Pharmaceuticals, 2018 (efavirenz +" exact="lamivudine" post="+ tenofovir disoproxil fumarate)Dovato, ViiV Healthcare, 2019 (dolutegravir +"/>
 <result pre="disoproxil fumarate)Symfi Lo, Mylan Pharmaceuticals, 2018 (efavirenz + lamivudine +" exact="tenofovir" post="disoproxil fumarate)Dovato, ViiV Healthcare, 2019 (dolutegravir + lamivudine) Fig."/>
 <result pre="Structures of nucleos(t)ide-based and non-nucleoside drugs used in combination with" exact="tenofovir" post="and lamivudine for the treatment of HIV infections. Abbreviations:"/>
 <result pre="nucleos(t)ide-based and non-nucleoside drugs used in combination with tenofovir and" exact="lamivudine" post="for the treatment of HIV infections. Abbreviations: NRTIs -"/>
 <result pre="One of the recently approved anti-HIV combinations, Biktarvy (bictegravir +" exact="emtricitabine" post="+ tenofovir alafenamide), is currently under phase 3 and"/>
 <result pre="the recently approved anti-HIV combinations, Biktarvy (bictegravir + emtricitabine +" exact="tenofovir" post="alafenamide), is currently under phase 3 and 4 clinical"/>
 <result pre="development of anti-HCV drugs. Treatments with pegylated interferon (PEG-IFN) and" exact="ribavirin" post="for HCV eradication have been replaced by the second"/>
 <result pre="the need for co-administration of INF. The high potency of" exact="sofosbuvir" post="is attributable, in part, to the first 5′-phosphate group,"/>
 <result pre="ZIKV RNA polymerases have very similar active sites, confirming that" exact="sofosbuvir" post="could also act on ZIKV-infected cells. It was also"/>
 <result pre="was also demonstrated via cellular assays and animal models that" exact="sofosbuvir" post="inhibits the replication of other flaviviruses, such as dengue"/>
 <result pre="bioavailability of some of the anti-herpesvirus drugs, such as acyclovir," exact="penciclovir" post="or ganciclovir, an amino acid esterification strategy is applied"/>
 <result pre="esterification strategy is applied to obtain compounds such as valaciclovir," exact="famciclovir" post="and valganciclovir, respectively. These &quot;prodrugs�? are rapidly converted into"/>
 <result pre="associated with its systemic use. The mechanism of action of" exact="idoxuridine" post="is not exactly defined, but the triphosphate inhibits viral"/>
 <result pre="both viral and cellular DNA. Currently, in the United States," exact="idoxuridine" post="is approved for only topical treatment of HSV keratitis,"/>
 <result pre="for only topical treatment of HSV keratitis, but in Europe," exact="idoxuridine" post="in DMSO is available for the treatment of herpes"/>
 <result pre="et al., 2010). The results of a comparison of brivudine," exact="famciclovir" post="and valaciclovir treatment in immunocompetent adult patients with herpes"/>
 <result pre="2010). The results of a comparison of brivudine, famciclovir and" exact="valaciclovir" post="treatment in immunocompetent adult patients with herpes zoster indicate"/>
 <result pre="of cancer cell lines. Compared to parent nucleoside, such as" exact="idoxuridine" post="or brivudine, which displayed only weak to moderate activity,"/>
 <result pre="in therapy for HSV-induced epithelial keratitis. After its conversion to" exact="trifluridine" post="monophosphate, it inhibits thymidylate synthetase, which is elevated in"/>
 <result pre="respect to thymidine triphosphate (Aoki, 2015). Trifluridine in combination with" exact="tipiracil" post="(Lonsurf) has been approved in Japan, the United States,"/>
 <result pre="colorectal cancer who were previously subjected to chemotherapy involving fluoropyrimidine," exact="oxaliplatin" post="and irinotecan (Burness and Duggan, 2016; Matsuoka et al.,"/>
 <result pre="who were previously subjected to chemotherapy involving fluoropyrimidine, oxaliplatin and" exact="irinotecan" post="(Burness and Duggan, 2016; Matsuoka et al., 2018). Phase"/>
 <result pre="tested as an antibacterial agent. Specifically, it was found that" exact="trifluridine" post="strongly inhibits Mycoplasma pneumoniae growth in vitro (Sun and"/>
 <result pre="acyclic guanosine analogues, namely, acyclovir, ganciclovir, valaciclovir, valganciclovir, penciclovir, and" exact="famciclovir" post="(Fig. 4). First, acyclovir (ACV, [9-(2-hydroxyethoxy)methyl)guanine]) was originally designed"/>
 <result pre="acyclovir (ACV, [9-(2-hydroxyethoxy)methyl)guanine]) was originally designed as an inhibitor of" exact="adenosine" post="deaminases, but in 1977, it was discovered to be"/>
 <result pre="specific enzymes (Weller et al., 1993). The oral bioavailability of" exact="valaciclovir" post="is much higher than that of acyclovir, reaching almost"/>
 <result pre="than that of acyclovir, reaching almost 50%. In clinical trials," exact="valaciclovir" post="has a similar antiviral activity and safety profile as"/>
 <result pre="the replicative function of the viral DNA polymerase. Unlike acyclovir," exact="penciclovir" post="is not considered a DNA chain terminator due to"/>
 <result pre="acyclic part of PCV, which allows DNA chain elongation. Incorporated" exact="penciclovir" post="probably distorts the DNA conformation and then induces the"/>
 <result pre="higher intracellular concentration compensate for the lower antiviral effect. Phosphorylated" exact="penciclovir" post="concentrations can be as much as 200-fold higher than"/>
 <result pre="acyclovir (Littler and Zhou, 2007; Kimberlin, 2018). The bioavailability of" exact="penciclovir" post="upon oral administration is poor, at approximately 5%; therefore,"/>
 <result pre="oral administration is poor, at approximately 5%; therefore, its prodrug" exact="famciclovir" post="(FCV, 6-deoxypenciclovir diacetate) was designed and approved for clinical"/>
 <result pre="mouse models have shown that the main advantage in using" exact="famciclovir" post="over using other drugs is its ability to prevent"/>
 <result pre="acyclic chain. Due to its highly efficient action against CMV," exact="ganciclovir" post="has been approved for use in the treatment of"/>
 <result pre="after oral administration (Jabs et al., 1986). For this reason," exact="ganciclovir" post="prodrugs have been explored. Valganciclovir (VGCV, 9-[(2-hydroxy-1-valyloxymethyl)ethoxymethyl]guanine), which was"/>
 <result pre="(over 60%). The addition of a valyl ester group to" exact="ganciclovir" post="makes it a good substrate of the two peptide"/>
 <result pre="its absorption. The ester linkage between the valyl group and" exact="ganciclovir" post="is easily hydrolysed by intestinal esterase and hepatic esterase"/>
 <result pre="et al., 2000). Vidarabine (VDR, 9-β-D-arabinofuranosyladenine) is an analogue of" exact="adenosine" post="isolated from Streptomyces antibioticus. Vidarabine, unlike previously discussed drugs,"/>
 <result pre="to generate an active metabolite. When phosphorylated by cellular enzymes," exact="vidarabine" post="is in the active triphosphate form. The lack of"/>
 <result pre="may also contribute to the antiviral and toxic effects of" exact="vidarabine" post="(Aoki, 2015; Theobald, 2016). Vidarabine was initially used as"/>
 <result pre="acyclovir-resistant herpesviruses. Due to its relative insolubility in aqueous media," exact="vidarabine" post="is mainly administered topically (Littler and Zhou, 2007). A"/>
 <result pre="Zhou, 2007). A few years ago, it was proposed that" exact="vidarabine" post="could be applied as a potent and selective inhibitor"/>
 <result pre="methylenecyclopropane nucleoside analogue structurally related to drugs such as acyclovir," exact="ganciclovir" post="and penciclovir. In vitro studies demonstrated its activity against"/>
 <result pre="tested in a phase 2 clinical trial in comparison with" exact="valaciclovir" post="for herpes zoster (NCT00900783) and in a phase 3"/>
 <result pre="and in a phase 3 clinical trial in comparison with" exact="valaciclovir" post="for the prevention of post-herpetic neuralgia (NCT02412917). Brincidofovir (CMX001),"/>
 <result pre="nelarabine, approved in 2005) and pyrimidine analogues (first approved in" exact="cytarabine" post="in 1969, gemcitabine in 1996, azacytidine in 2004, decitabine"/>
 <result pre="2005) and pyrimidine analogues (first approved in cytarabine in 1969," exact="gemcitabine" post="in 1996, azacytidine in 2004, decitabine in 2006, and"/>
 <result pre="in cytarabine in 1969, gemcitabine in 1996, azacytidine in 2004," exact="decitabine" post="in 2006, and floxuridine in 1970), which have had"/>
 <result pre="gemcitabine in 1996, azacytidine in 2004, decitabine in 2006, and" exact="floxuridine" post="in 1970), which have had important roles in several"/>
 <result pre="(Ianevski et al., 2018, 2019). Among them, the cytidine analogue" exact="gemcitabine" post="was reported to be 6th on the list of"/>
 <result pre="2019). Examples of such drugs include gemcitabine, zidovudine, 5-fluorouracil, floxuridine," exact="idoxuridine" post="and thiopurines. The application limitations of some nucleoside analogues"/>
 <result pre="replicating DNA (Cerqueira et al., 2007). Gemzar in combination with" exact="cisplatin" post="was approved in 1998 for the treatment of locally"/>
 <result pre="metastatic non-small cell lung cancer, and Gemzar in combination with" exact="paclitaxel" post="was approved as the first-line therapy for women battling"/>
 <result pre="cancer (at least 6 months after completion of platinum-based therapy)," exact="gemcitabine" post="is used in combination with carboplatin. Another study showed"/>
 <result pre="in combination with carboplatin. Another study showed that co-treatment with" exact="gemcitabine" post="and zidovudine re-sensitized gemcitabine-resistant pancreatic cancer by inhibiting the"/>
 <result pre="with carboplatin. Another study showed that co-treatment with gemcitabine and" exact="zidovudine" post="re-sensitized gemcitabine-resistant pancreatic cancer by inhibiting the key signalling"/>
 <result pre="phase 2 clinical trials have shown that combining brivudine with" exact="gemcitabine" post="or cisplatin enhanced their efficacy as a pancreatic cancer"/>
 <result pre="clinical trials have shown that combining brivudine with gemcitabine or" exact="cisplatin" post="enhanced their efficacy as a pancreatic cancer therapy (Heinrich"/>
 <result pre="been approved. Recently, experimental data on the antiviral activity of" exact="gemcitabine" post="have been widely reported (Shin et al., 2018; Ianevski"/>
 <result pre="et al., 2019). The broad range of viruses against which" exact="gemcitabine" post="has shown activity includes HIV-1 (Rawson et al., 2013;"/>
 <result pre="and FLUAV (Denisova et al., 2012). The synergistic effect of" exact="gemcitabine" post="combined with low doses of other nucleoside analogues was"/>
 <result pre="analogues was also reported. It is applied in combination with" exact="ribavirin" post="for the treatment of enteroviruses or with decitabine for"/>
 <result pre="combination with ribavirin for the treatment of enteroviruses or with" exact="decitabine" post="for the treatment of HIV (Kang et al., 2015;"/>
 <result pre="et al., 2015; Clouser et al., 2010). In most cases," exact="gemcitabine" post="inhibits viruses at low, non-cytotoxic concentrations (Denisova et al.,"/>
 <result pre="al., 2012; Kuivanen et al., 2017). Depending on the virus," exact="gemcitabine" post="was shown to be an inhibitor of viral replication,"/>
 <result pre="viral replication, proliferation, RNA and protein synthesis, or production. The" exact="gemcitabine" post="antiviral effect on enteroviruses was proposed to be based"/>
 <result pre="cellular DNA or RNA synthesis. It is also possible that" exact="gemcitabine" post="can block the RNA polymerase by binding to the"/>
 <result pre="nucleoside available (Song et al., 2017). As a cytidine analogue," exact="gemcitabine" post="was reported to inhibit the salvage pathway of the"/>
 <result pre="the salvage pathway of the pyrimidine biosynthesis. Additionally, treatment with" exact="gemcitabine" post="activates the expression of several IFN-stimulated genes (including CXCL10,"/>
 <result pre="phenomenon could in turn be overcome by the combination of" exact="gemcitabine" post="and gentamicin, which showed synergistic activity and reduced the"/>
 <result pre="silenced (Wolff et al., 2017). Experimental studies have shown that" exact="azacitidine" post="is a potent, broad-spectrum antiviral agent. The range of"/>
 <result pre="rapidly dividing cells by disrupting DNA synthesis. Similar to azacytidine," exact="decitabine" post="also induces immune responses and sensitizes tumours to checkpoint"/>
 <result pre="Additionally, it was shown that in muscle-invasive bladder cancer cells," exact="decitabine" post="treatment (at low non-cytotoxic doses) restored NOTCH1 expression and"/>
 <result pre="CK5 differentiation (Ramakrishnan et al., 2017). The antiviral activity of" exact="decitabine" post="has been shown mostly in HIV treatment. Similar to"/>
 <result pre="described synergistic effect of azacytidine with resveratrol, the combination of" exact="decitabine" post="and resveratrol significantly reduced the levels of HIV-1 reverse"/>
 <result pre="et al., 2016b). Another study indicated that the combination of" exact="gemcitabine" post="and decitabine at concentrations much lower than those used"/>
 <result pre="2016b). Another study indicated that the combination of gemcitabine and" exact="decitabine" post="at concentrations much lower than those used in cancer"/>
 <result pre="et al., 2014). Further study on the anti-HIV-1 activity of" exact="clofarabine" post="revealed its dual inhibitory function in virus replication. It"/>
 <result pre="revealed through an integrated network analysisbioRxiv 1–232019 Bullard-FeibelmanK.M.GoveroJ.ZhuZ.SalazarV.VeselinovicM.DiamondM.S.GeissB.J.The FDA-approved drug" exact="sofosbuvir" post="inhibits Zika virus infectionAntivir. Res.137201713414010.1016/j.antiviral.2016.11.02327902933 BurnessC.B.DugganS.T.Trifluridine/tipiracil: a review in"/>
 <result pre="beyondAntivir. Res.1552018768810.1016/j.antiviral.2018.05.00529758235 ClouserC.L.HoltzC.M.MullettM.CrankshawD.L.BriggsJ.E.O'SullivanM.G.PattersonS.E.ManskyL.M.Activity of a novel combined antiretroviral therapy of" exact="gemcitabine" post="and decitabine in a mouse model for HIV-1Antimicrob. Agents"/>
 <result pre="ClouserC.L.HoltzC.M.MullettM.CrankshawD.L.BriggsJ.E.O'SullivanM.G.PattersonS.E.ManskyL.M.Activity of a novel combined antiretroviral therapy of gemcitabine and" exact="decitabine" post="in a mouse model for HIV-1Antimicrob. Agents Chemother.5620121942194810.1128/aac.06161-1122271861 ClouserC.L.PattersonS.E.ManskyL.M.Exploiting"/>
 <result pre="over the past 50 yearsClin. Microbiol. Rev.29201669574710.1128/CMR.00102-15Address27281742 De ClercqE.Role of" exact="tenofovir" post="alafenamide (TAF) in the treatment and prophylaxis of HIV"/>
 <result pre="zosterBiochem. Pharmacol.6820042301231510.1016/j.bcp.2004.07.03915548377 De FreitasC.S.HigaL.M.SacramentoC.Q.FerreiraA.C.ReisP.A.DelvecchioR.MonteiroF.L.Barbosa-LimaG.James WestgarthH.VieiraY.R.MattosM.RochaN.HoelzL.V.B.LemeR.P.P.BastosM.M.RodriguesG.O.L.LopesC.E.M.Queiroz-JuniorC.M.LimaC.X.CostaV.V.TeixeiraM.M.BozzaF.A.BozzaP.T.BoechatN.TanuriA.SouzaT.M.L.Yellow fever virus is susceptible to" exact="sofosbuvir" post="both in vitro and in vivoPLoS Neglected Trop. Dis.132019e000707210.1371/journal.pntd.0007072"/>
 <result pre="and in vivoPLoS Neglected Trop. Dis.132019e000707210.1371/journal.pntd.0007072 DenisovaO.V.KakkolaL.FengL.StenmanJ.NagarajA.LampeJ.YadavB.AittokallioT.KaukinenP.AholaT.KuivanenS.VapalahtiO.KanteleA.TynellJ.JulkunenI.Kallio-KokkoH.PaavilainenH.HukkanenV.ElliottR.M.De BrabanderJ.K.SaelensX.KainovD.E.Obatoclax, saliphenylhalamide, and" exact="gemcitabine" post="inhibit influenza A virus infectionJ. Biol. Chem.2872012353243533210.1074/jbc.M112.39214222910914 DiamantopoulosP.T.MichaelM.BenopoulouO.BazanisE.TzeletasG.MeletisJ.VayopoulosG.ViniouN.A.Antiretroviral activity"/>
 <result pre="Gouveia PedrosaC.SouzaL.R.Q.LoiolaE.C.TrindadeP.VieiraY.R.Barbosa-LimaG.de Castro Faria NetoH.C.BoechatN.RehenS.K.BrüningK.BozzaF.A.BozzaP.T.SouzaT.M.L.Beyond members of the Flaviviridae family," exact="sofosbuvir" post="also inhibits chikungunya virus replicationAntimicrob. Agents Chemother.63201910.1128/AAC.01389-18e01389-18 FlorescuD.F.PergamS.A.NeelyM.N.QiuF.JohnstonC.WayS.S.SandeJ.LewinsohnD.A.Guzman-CottrillJ.A.GrahamM.L.PapanicolaouG.KurtzbergJ.RigdonJ.PainterW.Mommeja-MarinH.LanierR.AndersonM.van der"/>
 <result pre="Res. Clin. Oncol.13720111349136110.1007/s00432-011-1005-121833720 HertelL.W.BoderG.B.KroinJ.S.RinzelS.M.PooreG. aToddG.C.GrindeyG.B.Evaluation of the antitumor activity of" exact="gemcitabine" post="(2 ′ , 2 ′ evaluation of the antitumor"/>
 <result pre="and in a mouse modelAntivir. Res.1372017142210.1016/j.antiviral.2016.11.00327838352 KaminskasE.FarrellA.T.WangY.-ChSridharaR.PazdurR.FDA drug approval summary:" exact="azacitidine" post="(5-azacytidine, Vidaza) for injectable suspensionThe Oncologist10200517618210.1634/theoncologist.10-3-17615793220 KangH.KimC.KimD.E.SongJ.H.ChoiM.ChoiK.KangM.LeeK.KimH.S.ShinJ.S.KimJ.HanS.B.LeeM.Y.LeeS.U.LeeC.K.KimM.KoH.J.Van KuppeveldF.J.M.ChoS.Synergistic antiviral"/>
 <result pre="Vidaza) for injectable suspensionThe Oncologist10200517618210.1634/theoncologist.10-3-17615793220 KangH.KimC.KimD.E.SongJ.H.ChoiM.ChoiK.KangM.LeeK.KimH.S.ShinJ.S.KimJ.HanS.B.LeeM.Y.LeeS.U.LeeC.K.KimM.KoH.J.Van KuppeveldF.J.M.ChoS.Synergistic antiviral activity of" exact="gemcitabine" post="and ribavirin against enterovirusesAntivir. Res.124201511010.1016/j.antiviral.2015.10.01126526589 KimberlinD.W.Antiviral Agents. Principles and"/>
 <result pre="injectable suspensionThe Oncologist10200517618210.1634/theoncologist.10-3-17615793220 KangH.KimC.KimD.E.SongJ.H.ChoiM.ChoiK.KangM.LeeK.KimH.S.ShinJ.S.KimJ.HanS.B.LeeM.Y.LeeS.U.LeeC.K.KimM.KoH.J.Van KuppeveldF.J.M.ChoS.Synergistic antiviral activity of gemcitabine and" exact="ribavirin" post="against enterovirusesAntivir. Res.124201511010.1016/j.antiviral.2015.10.01126526589 KimberlinD.W.Antiviral Agents. Principles and Practice of"/>
 <result pre="Practice of Pediatric Infectious DiseasesFifth. ed2018 KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.De BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and" exact="gemcitabine" post="inhibit Zika virus infection in vitro and differentially affect"/>
 <result pre="NambaT.KodamaR.MoritomoS.HoshinoT.MizushimaT.Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to" exact="gemcitabine" post="by inhibition of the Akt-GSK3β-Snail pathwayCell Death Dis.6201511110.1038/cddis.2015.172 NikkeisA.F.PiérardG.E.Recognition"/>
 <result pre="hepatitis C virusJ. Med. Chem.5320107202721810.1021/jm100863x20845908 SongJ.H.KimS.R.HeoE.Y.LeeJ.Y.KimD. eunChoS.ChangS.Y.YoonB. IlSeongJ.KoH.J.Antiviral activity of" exact="gemcitabine" post="against human rhinovirus in vitro and in vivoAntivir. Res.145201761310.1016/j.antiviral.2017.07.00328705625"/>
 <result pre="inhibitors azacytidine and decitabineInt. J. Cancer123200881310.1002/ijc.2360718425818 SugawaraM.HuangW.FeiY.J.LeibachF.H.GanapathyV.GanapathyM.E.Transport of valganciclovir, a" exact="ganciclovir" post="prodrug, via peptide transporters PEPT1 and PEPT2J. Pharm. Sci.89200078178910.1002/(SICI)1520-6017(200006)89:6&amp;lt;781::AID-JPS10&amp;gt;3.0.CO;2-710824137"/>
 <result pre="anticancer and antiviral nucleoside and nucleobase analogsBMC Microbiol.13201318410.1186/1471-2180-13-18423919755 ThackrayA.M.FieldH.J.Famciclovir and" exact="valaciclovir" post="differ in the prevention of herpes simplex virus type"/>
 <result pre="Physiol. Cell Physiol.3052013H1H810.1152/ajpheart.00080.2013 WellerS.BlumM.R.DoucetteM.BurnetteT.CederbergD.M.MirandaP. DeSmileyM.L.Pharmacolunetics of the acvclovir pro- drug" exact="valaciclovir" post="after iscalati and multiple-dose adrninis tration normal volunteersClin. Pharmacol."/>
 <result pre="nucleoside scaffoldAntivir. Res.162201952110.1016/j.antiviral.2018.11.01630529089 ZhangZ.YangE.HuC.ChengH.ChenC.Y.HuangD.WangR.ZhaoY.RongL.VignuzziM.ShenH.ShenL.ChenZ.W.Cell-based high-throughput screening assay identifies 2′,2′- difluoro-2′-deoxycytidine" exact="gemcitabine" post="as a potential antipoliovirus agentACS Infect. Dis.32017455310.1021/acsinfecdis.6b0011627733043"/>
</results>
